Results 101 to 110 of about 591 (191)

Crátera de Toya

open access: yes, 2014
Detalle de una mujer tocando la doble flauta o ...
Fernández Ruíz, Eugenio
core   +2 more sources

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. [PDF]

open access: yesBr J Cancer, 2023
Desai J   +13 more
europepmc   +1 more source

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. [PDF]

open access: yesCurr Oncol
Williamson J   +18 more
europepmc   +1 more source

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. [PDF]

open access: yesNat Cancer
Kendra KL   +32 more
europepmc   +1 more source

Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance. [PDF]

open access: yesClin Cancer Res
Liu J   +19 more
europepmc   +1 more source

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. [PDF]

open access: yesBr J Cancer, 2023
Friedlander M   +14 more
europepmc   +1 more source

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors. [PDF]

open access: yesCancer Res Commun
Powderly J   +20 more
europepmc   +1 more source

Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. [PDF]

open access: yesJ Clin Oncol
Sharma MR   +25 more
europepmc   +1 more source

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. [PDF]

open access: yesCancer Res Commun, 2023
Weidhaas JB   +19 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy